Metagenomi Therapeutics is no longer selling a broad gene-editing toolbox. After the late-2025 reset that cut a quarter of the staff and replaced the founder chief executive, the listed company is a single-asset hemophilia A development story sitting on more cash than equity value. Jian Irish now runs a narrowed Emeryville operator whose public identity hangs on getting MGX-001 into the clinic. The market already treats that identity as optional.
The scientific case is the November primate work, where the proposed clinical dose produced average Factor Eight activity near half of normal. That is the argument for a one-time albumin-locus integration versus chronic mimetics. The financial case moved the other way. Collaboration revenue flipped negative after the April Ionis modification and a catch-up charge, leaving a cash pile near $121 million against a mid-September capitalization near $42 million. Partnership income is no longer a reliable funding engine.
Second-quarter research spending held flat while overhead declined, which is the cost shape of a company that already did its layoff. Management still points to a year-end investigational new drug filing and a cash runway through late 2027. The open question is whether regulators accept a dual-vector integration package before any human data, or whether the equity keeps trading as a discounted cash box until clinic entry.